TCR² Therapeutics to Participate in Two Upcoming Conferences in March
March 03 2021 - 8:00AM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage
immunotherapy company with a pipeline of novel T cell therapies for
patients suffering from cancer, today announced that management
will present an update on Company progress at two upcoming
conferences in March using a virtual platform.
- Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, will
present corporate presentation at the H.C. Wainwright Global Life
Sciences Conference on March 9, 2021 at 7:00am ET
- Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, and
Robert Hofmeister, Ph.D., Chief Scientific Officer of TCR2
Therapeutics, will participate in a fireside chat at the 33rd
Annual Roth Conference on March 17, 2021 at 11:00am ET
A live webcast of the presentation will be
available on the Investors page of the Company’s website at
www.investors.tcr2.com. An archived replay will be available for at
least 30 days following the presentation.
About TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage immunotherapy company developing a pipeline of novel
T cell therapies for patients suffering from solid tumors or
hematological malignancies. TCR2’s proprietary T cell
receptor (TCR) Fusion Construct T cells (TRuC®-T cells)
specifically recognize and kill cancer cells by harnessing
signaling from the entire TCR, independent of human leukocyte
antigens (HLA). In preclinical studies, TRuC-T cells have
demonstrated superior anti-tumor activity compared to chimeric
antigen receptor T cells (CAR-T cells), while secreting lower
levels of cytokine release. The Company’s lead TRuC-T cell product
candidate targeting solid tumors, gavo-cel, is currently being
studied in a Phase 1/2 clinical trial to treat patients with
mesothelin-positive non-small cell lung cancer (NSCLC), ovarian
cancer, malignant pleural/peritoneal mesothelioma, and
cholangiocarcinoma. The Company’s lead TRuC-T cell product
candidate targeting hematological malignancies, TC-110, is
currently being studied in a Phase 1/2 clinical trial to treat
patients with CD19-positive adult acute lymphoblastic leukemia
(aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
For more information about TCR2, please
visit www.tcr2.com.
Investor and Media Contact:
Carl MauchDirector, Investor Relations and
Corporate CommunicationsTCR2 Therapeutics Inc.(617)
949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Sep 2024 to Oct 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Oct 2023 to Oct 2024